Edwards Lifesciences (EW): Officer sold ~$2.01M
Donald E Jr Bobo, Officer at Edwards Lifesciences, sold ~$2.01M of Edwards Lifesciences shares.
- ~$2.01M
- Approx. value · 24K sh @ $83.84
- 21K
- Holds after · shares reported
- Traded
- Feb 25, 2026
- Filed
- Feb 27, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 19, 2025CongressDisclosed sale of EW — reported range $1,001 - $15,000
- Jan 6, 2026Insider · 1 personInsiders: 2 sales (~$971K)
- Jan 9, 2026InsiderOfficer sold ~$87K of EW shares in the open market
- Feb 10, 2026Company filing · Form 8-K · ResultsReported its results
- Feb 12, 2026Insider · 1 personInsiders: 2 sales (~$1.7M)
- Feb 24, 2026FDAFDA device clearance: HemoSphere Nano Monitor (HSNANO1)
- Feb 25, 2026 · this disclosureInsiderOfficer sold ~$2.01M of EW shares in the open market
What came next
- Mar 2, 2026InsiderOfficer sold ~$974K of EW shares in the open market
- Mar 11, 2026Insider · 2 peopleInsiders: 3 sales (~$1.2M)
- Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Mar 27, 2026FDARecall: Edwards EVOQUE tricuspid delivery system REF:9850TDS Sterile EO
- Apr 2, 2026Insider · 1 personInsiders: 2 sales (~$1.8M)
- Apr 6, 2026InsiderOfficer sold ~$83K of EW shares in the open market
- Apr 9, 2026Insider · 1 personInsiders: 2 sales (~$1.0M)
- Apr 17, 2026FDAFDA device clearance: Edwards eSheath+ introducer set
- Apr 23, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- May 1, 2026Insider · 1 personInsiders: 2 sales (~$85K)
- May 2, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.”
- May 4, 2026InsiderOfficer sold ~$86K of EW shares in the open market
- May 7, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“of Certain Officers Approval of the Amended and Restated Long-Term Stock Incentive Compensation Program At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term Stock Incentive Compensation Program (the “Long-Term Stock Program”).”
- May 11, 2026InsiderOfficer sold ~$47K of EW shares in the open market
- May 12, 2026Insider · 1 personInsiders: 2 sales (~$2.8M)
- May 15, 2026Insider · 1 personInsiders: 2 sales (~$1.5M)
- May 18, 2026InsiderOfficer sold ~$50K of EW shares in the open market
- May 22, 2026InsiderOfficer sold ~$127K of EW shares in the open market
- May 27, 2026InsiderOfficer sold ~$2M of EW shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Edwards Lifesciences
For Edwards Lifesciences, OQRO holds 14 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EW page.
Other recent filings by Donald E Jr Bobo, CVP,Strategy/Corp Development
- SEC Form 4 at Edwards Lifesciences (EW)Nov 9, 2026
- SEC Form 4 at Edwards Lifesciences (EW)May 27, 2026
- SEC Form 4 at Edwards Lifesciences (EW)May 18, 2026
- SEC Form 4 at Edwards Lifesciences (EW)May 18, 2026
- SEC Form 4 at Edwards Lifesciences (EW)Apr 2, 2026
The full history of Donald E Jr Bobo, CVP,Strategy/Corp Development is on the profile page.
How this filing works
Explore the data
Common questions
Which Edwards Lifesciences (EW) insider traded, and how much?
Donald E Jr Bobo, Officer at Edwards Lifesciences, sold ~$2.01M of Edwards Lifesciences shares. 24K shares at $83.84.
When did it happen, and when was it made public?
Traded: Feb 25, 2026. Filed: Feb 27, 2026. That is 2 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Edwards Lifesciences recently?
For Edwards Lifesciences, OQRO holds 14 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the EW page.
Does this mean EW stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Edwards Lifesciences
- SEC Form 13F-HRNov 16, 2026
- SEC Form 144Nov 10, 2026
- SEC Form 4Nov 10, 2026
- SEC Form 144Nov 9, 2026
- SEC Form 144Nov 9, 2026
- SEC Form 4Nov 9, 2026
Everything OQRO holds on this company is on its EW page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
